<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Head Face Med</journal-id>
      <journal-title-group>
        <journal-title>Head &amp; Face Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-160X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21849044</article-id>
      <article-id pub-id-type="pmc">3175443</article-id>
      <article-id pub-id-type="publisher-id">1746-160X-7-16</article-id>
      <article-id pub-id-type="doi">10.1186/1746-160X-7-16</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Cella</surname>
            <given-names>Luigi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>L.CELLA@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Oppici</surname>
            <given-names>Aldo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>A.Oppici@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Arbasi</surname>
            <given-names>Mariacristina</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>m.arbasi@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Moretto</surname>
            <given-names>Mauro</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>m.moretto@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Piepoli</surname>
            <given-names>Massimo</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>m.piepoli@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Vallisa</surname>
            <given-names>Daniele</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>d.vallisa@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Zangrandi</surname>
            <given-names>Adriano</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>a.zangrandi@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Di Nunzio</surname>
            <given-names>Camilla</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>C.DiNunzio@ausl.pc.it</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A9">
          <name>
            <surname>Cavanna</surname>
            <given-names>Luigi</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>l.cavanna@ausl.pc.it</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Departments of Oral and Maxillofacial Surgery, Hospital of Piacenza, Via Taverna, 49. 29100. Italy</aff>
      <aff id="I2"><label>2</label>Department of Immunohematology, Hospital of Piacenza, Via Taverna, 49. 29100. Italy</aff>
      <aff id="I3"><label>3</label>Department of Cardiology, Hospital of Piacenza, Via Taverna, 49. 29100. Italy</aff>
      <aff id="I4"><label>4</label>Department of Oncology and Hematology, Hospital of Piacenza, Via Taverna, 49. 29100. Italy</aff>
      <aff id="I5"><label>5</label>Department of Pathology, Hospital of Piacenza, Via Taverna, 49. 29100. Italy</aff>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <volume>7</volume>
      <fpage>16</fpage>
      <lpage>16</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>5</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>8</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 Cella et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Cella et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.head-face-med.com/content/7/1/16"/>
      <abstract>
        <sec>
          <title>Purpose</title>
          <p>Bisphosphonate - related osteonecrosis of the JAW (BRONJ) is a well known side effect of bisphosphonate therapies in oncologic and non oncologic patients. Since to date no definitive consensus has been reached on the treatment of BRONJ, novel strategies for the prevention, risk reduction and treatment need to be developed. We report a 75 year old woman with stage 3 BRONJ secondary to alendronate and pamidronate treatment of osteoporosis. The patient was unresponsive to recommended treatment of the disease, and her BRONJ was worsening. Since bone marrow stem cells are know as being multipotent and exhibit the potential for differentiation into different cells/tissue lineages, including cartilage, bone and other tissue, we performed autologous bone marrow stem cell transplantation into the BRONJ lesion of the patient.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Under local anesthesia a volume of 75 ml of bone marrow were harvested from the posterior superior iliac crest by aspiration into heparinized siringes. The cell suspension was concentrated, using Ficoll - Hypaque<sup>&#xAE; </sup>centrifugation procedures, in a final volume of 6 ml. Before the injection of stem cells into the osteonecrosis, the patient underwent surgical toilet, local anesthesia was done and spongostan was applied as a carrier of stem cells suspension in the bone cavity, then 4 ml of stem cells suspension and 1 ml of patient's activated platelet-rich plasma were injected in the lesion of BRONJ.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>A week later the residual spongostan was removed and two weeks later resolution of symptoms was obtained. Then the lesion improved with progressive superficialization of the mucosal layer and CT scan, performed 15 months later, shows improvement also of bone via concentric ossification: so complete healing of BRONJ (stage 0) was obtained in our patient, and 30 months later the patient is well and without signs of BRONJ.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>To our knowledge this is the first case of BRONJ successfully treated with autologous stem cells transplantation with a complete response.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Osteonecrosis of the Jaw</kwd>
        <kwd>bisphoshonate</kwd>
        <kwd>stem cell transplantation</kwd>
        <kwd>organ repair</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Bisphosphonates are widely used in the management of bone diseases including osteoporosis, Paget's disease, hypercalcemia related to malignancy and in the prevention of skeletal complication from bone metastasis. Bisphosphonates are incorporated into skeleton and suppress bone resorption, without being degraded [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Bisphosphonates have shown direct anti-tumor effects, possibly related to growth factors release reduction and inhibition of cell adhesion molecules [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Bisphosphonates - related osteonecrosis of the Jaw (BRONJ) has been characterized as a main side effect of bisphosphonate therapy [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. The most frequent clinical sign of BRONJ is bone exposure, associated with pain, swelling and purulent secretion that does not heal over a period of 6-8 weeks [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. To date no definitive consensus has been reached on the treatment of BRONJ and several studies reported relatively conflicting results following surgery, antibiotics, laser or hyperbaric oxygen administration [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. For this reason, new strategies for the prevention, risk reduction and treatment for BRONJ need to be developed [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B20">20</xref>].</p>
      <p>Bone marrow harvested stem cells and progenitor cells (BMSC) may be capable of solid-organ repair [<xref ref-type="bibr" rid="B21">21</xref>], and it has been demonstrated that adult human mesenchymal stem cells (MSC) from bone marrow can represent a promising source for skeletal regeneration [<xref ref-type="bibr" rid="B22">22</xref>].</p>
      <p>Based on these data, we report here a patient with BRONJ, unresponsive to the recommended procedures, that showed clinical and radiographic improvement after autologous bone marrow stem cells intralesional transplantation.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>In January 2008 a 75 year old woman was referred to us for a stage III BRONJ of the mandible (Figure <xref ref-type="fig" rid="F1">1</xref>); she was previously treated for a severe osteoporosis with alendronate 70 mg every four weeks for 9 months, then pamidronate 60 mg every four weeks for two years. In the same period the patient was treated with Eritropoietin beta (EPO) for three years (10.000 U/weeks) for a mild renal failure related anemia. BRONJ was defined in accordance with the American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonates - related osteonecrosis of the Jaws [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B17">17</xref>] and all the three characteristics were present in the patient:</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Clinical onset and appearance of BRONJ stage III</bold>.</p>
        </caption>
        <graphic xlink:href="1746-160X-7-16-1"/>
      </fig>
      <p>1. Current or previous treatment with a bisphosphonate;</p>
      <p>2. Exposed bone in the maxillofacial region that has persisted fore more 8 weeks;</p>
      <p>3. No history of radiation therapy to the jaws.</p>
      <p>Conservative, non - surgical treatment was initially performed, as recommended [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B20">20</xref>], such as oral hygiene (brushing and mouth rinses), topical and systemic antibiotics active against common oral/dental bacterial infection; subsequently both debridement, toilet of exposed bone and Er:YAG laser treatment were uneffective [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>] and patient's conditions deteriorated with pain and worsening of BRONJ progressively. Computed Tomography (CT) scan showed bone destruction (Figure <xref ref-type="fig" rid="F2">2</xref>). Resection and immediate reconstruction was proposed to the patient, however she refused resection, as recommended [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Clinical Onset: computed tomography scan shows bone destruction</bold>.</p>
        </caption>
        <graphic xlink:href="1746-160X-7-16-2"/>
      </fig>
      <p>The concept that bone marrow stem cells upon transplantation into adult recipients transdifferentiate and contribute to the rigeneration of a variety of non -hematopoietic lineages in multiple organs, has provoked great interest for its potential clinical applications [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>] as recently reported also by our group [<xref ref-type="bibr" rid="B26">26</xref>]. So we offered the opportunity to our patient of injection of autologous bone marrow stem cells into the osteonecrosis site lesion.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>In september 2008 the patient (who is the mother of one of us) was informed about the procedure and gave written informed consent.</p>
      <p>Under local anesthesia an average of 75 ml of bone marrow were harvested from the posterior superior iliac crest by aspiration into heparinized syringes as previously reported by our group [<xref ref-type="bibr" rid="B26">26</xref>]. Progenitor cells were isolated and enriched using Ficoll - Hypaque<sup>&#xAE; </sup>centrifugation procedures. This procedure allowed the depletion of mature myeloid and erythroid cell from the harvest. The cell suspension consisted of an heterogeneous cell population including hematopoietic, mesenchymal, endothelial and other progenitor cells as well as mononuclear cells. The cells were suspended into an opportune quantity of PBS-EDTA buffer containing 5% of human albumin.</p>
      <p>The cell fraction was concentrated in a final volume of 6 ml. Finally, before intralesional transplantation, the cells were subjected to quality control procedures (i.e. sterility test for aerobic and anaerobic bacteria, Elisa test for HCV, HBV, HIV viruses) in order to exclude any contamination as previously reported [<xref ref-type="bibr" rid="B26">26</xref>]. In addition, full blood count and immune-phenotype analyses of the cell suspension were performed, including absolute CD34 and CD45 positive cell count and five colour MoAb panel for the identification of the cellular subpopulation (Table <xref ref-type="table" rid="T1">1</xref>).</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Multiparameter flow cytometric analysis of the injected BMC</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left">Cellular subset</th>
              <th align="left">harvest (ml 75)</th>
              <th align="left">final (ml 6)</th>
              <th align="left">injected (ml 4)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">nuclear cells/ul (total E<sup>6</sup>)</td>
              <td align="left">16.800/ul (1.260)</td>
              <td align="left">71.000/ul (426)</td>
              <td/>
            </tr>
            <tr>
              <td align="left">WBC (CD45<sup>+</sup>) (E<sup>6</sup>) *</td>
              <td align="left">875,7</td>
              <td align="left">252</td>
              <td align="left">168</td>
            </tr>
            <tr>
              <td align="left">CD 34+ cells/ul</td>
              <td align="left">95,2</td>
              <td align="left">800</td>
              <td align="left">800</td>
            </tr>
            <tr>
              <td align="left">CD 34+ cells (E<sup>6</sup>)</td>
              <td align="left">7,14</td>
              <td align="left">4,8</td>
              <td align="left">3,2</td>
            </tr>
            <tr>
              <td align="left">CD34+/CD117+ cells (E<sup>6</sup>)</td>
              <td align="left">5,64</td>
              <td align="left">4,22</td>
              <td align="left">2,8</td>
            </tr>
            <tr>
              <td align="left">CD34+/CD133+ cells (E<sup>6</sup>)</td>
              <td align="left">3,42</td>
              <td align="left">1,15</td>
              <td align="left">0,76</td>
            </tr>
            <tr>
              <td align="left">CD45-/CD31+ cells (E<sup>6</sup>)</td>
              <td align="left">2,64</td>
              <td align="left">0,97</td>
              <td align="left">0,64</td>
            </tr>
            <tr>
              <td align="left">CD133+/CD117+ cells (E<sup>6</sup>)</td>
              <td align="left">4,1</td>
              <td align="left">1,95</td>
              <td align="left">1,3</td>
            </tr>
            <tr>
              <td align="left">CD133+ cells (E<sup>6</sup>)</td>
              <td align="left">5,92</td>
              <td align="left">2,25</td>
              <td align="left">1,5</td>
            </tr>
            <tr>
              <td align="left">CD117+ cells (E<sup>6</sup>)</td>
              <td align="left">28</td>
              <td align="left">20,2</td>
              <td align="left">13,5</td>
            </tr>
            <tr>
              <td align="left">CD45-/CD105+/CD71- cells (E<sup>6</sup>)</td>
              <td align="left">302,2</td>
              <td align="left">255,6</td>
              <td align="left">170</td>
            </tr>
            <tr>
              <td align="left">Ficoll mediated myeloid depletion % *</td>
              <td/>
              <td/>
              <td/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>BMC: Bone marrow cells</p>
        </table-wrap-foot>
      </table-wrap>
      <p>Before the injection of stem cells into the osteonecrosis the patient underwent a surgical toilet in local anesthesia of the bone lesion.</p>
      <p>The bone cavity was fullfilled with fibrine sponge (Spongostan<sup>&#xAE;</sup>) as a carrier, then 4 ml of stem cells suspension and 1 ml of patient's activated platelet-rich plasma were injected in the lesion of BRONJ.</p>
    </sec>
    <sec>
      <title>Results</title>
      <p>The procedure was well tolerated, and a week later the dehiscence of the surgical wound was observed, the residual carrier was removed. Then a soft, uniform layer of whitish mucosa dressing the bone cavity was observed. Two weeks later, resolution of symptoms was obtained and the lesion improved (Figure <xref ref-type="fig" rid="F3">3</xref>) with the pink coloured new layer. Subsequently the patient was seen at our out patients dental-maxillofacial service every two weeks for six months, then every four weeks and showed a progressive improvement. Clinical controls showed progressive improvement of the mucosal layer (Figure <xref ref-type="fig" rid="F4">4</xref>). CT scan performed 15 months later showed improvement of bone and concentric ossification (Figure <xref ref-type="fig" rid="F5">5</xref>). A complete healing of BRONJ (stage 0) was obtained and the patient is well without sings of BRONJ 30 months later. To our knowledge this is the first case of BRONJ treated with autologous stem cells injection.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Two weeks later after bone marrow cells transplantation: pink coloured new layer shows progressive improvement of the mucosa</bold>.</p>
        </caption>
        <graphic xlink:href="1746-160X-7-16-3"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p><bold>Four months later: the lesion of the mucosa is ulteriorly improved</bold>.</p>
        </caption>
        <graphic xlink:href="1746-160X-7-16-4"/>
      </fig>
      <fig id="F5" position="float">
        <label>Figure 5</label>
        <caption>
          <p><bold>Computed Tomography scan, 15 months later, shows a concentric ossification of the bone lesion</bold>.</p>
        </caption>
        <graphic xlink:href="1746-160X-7-16-5"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Since the first description by Marx, 2003 [<xref ref-type="bibr" rid="B27">27</xref>]and Wang et al 2003 [<xref ref-type="bibr" rid="B28">28</xref>], cases with BRONJ are being increasingly reported, first of all, in oncologic patients in line with the increased use of bisphosphonates (mainly zolendronate and pamidronate) as the main pathogenetic factor of BRONJ.</p>
      <p>A review of the literature through march 2006 performed by our group [<xref ref-type="bibr" rid="B9">9</xref>] identified more than 250 reported case on BRONJ, and more recently over 6.000 cases have been reported to the US Food and Drug Administration [<xref ref-type="bibr" rid="B29">29</xref>]. The treatment goals for patients with an established diagnosis of BRONJ are, as recently reported [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B20">20</xref>], to eliminate pain, to control infection of the soft and hard tissue and to minimize the occurrence or the progression of bone necrosis.</p>
      <p>However the response to treatments of the patients with BRONJ is less predictable than the established surgical treatment modalities for osteomyelitis or osteoradionecrosis, and new treatment procedures need to be developed [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B20">20</xref>].</p>
      <p>From the hystopathological point of view the BRONJ is characterized by an avascular necrosis. In osteonecrosis is found a lack of osteogenic precursor cells that derive from mesenchymal stem cells (MSCs), but also a lack in vascular support that derives from endothelial progenitor cells (EPCs).</p>
      <p>MSCs are known as being multipotent and exhibit the potential for differentiation into different cell/tissue lineages, including cartilage, bone, adipose tissue, tendon and ligament [<xref ref-type="bibr" rid="B30">30</xref>]. These pluripotent mesenchymal progenitor cell are denoted as stromal or mesenchymal stem cells.</p>
      <p>In vivo osteogenesis occurs only if the density of implanted cells at the treated site is sufficiently high. To achieve this goal, either large amounts of concentrated bone marrow stem cells or bone marrow stem cells in combination with growth factors can be used [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>].</p>
      <p>This situation has been reproduced by in vitro studies which confirmed that composite implantation of mesenchymal stem cells with endothelial progenitor cells enhances tissue-engineered bone formation [<xref ref-type="bibr" rid="B33">33</xref>].</p>
      <p>The homing mechanisms of MSCs are poorly understood; it is known that, based on chemokine/chemokine-receptor interactions and adhesion molecules, MSCs are potentially capable on finding the site of injury and when, given intravenously, of restoring damaged tissue on site due to their plasticity and/or paracrine properties [<xref ref-type="bibr" rid="B30">30</xref>]. However, it must be emphasized that a direct approach, bringing direct into the osteonecrotic site a significant amount of bone marrow enriched in mononuclear cells, could allow a better osteogenesis of the damaged bone based on evidence data of the presence in this cell-fraction of osteoid and angiogenic precursors [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B36">36</xref>].</p>
      <p>Bone marrow contains three main cell lines: hematopoietic cells, mesenchymal and proendotelial cells [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. Recently we reported in a randomized controlled trial the effects of intracoronary transfer of autologous bone marrow stem cells in patients with acute anterior myocardial infarction and we demonstrated that this procedure improves cardiac, autonomic, and functional indexes in this setting of treated patients [<xref ref-type="bibr" rid="B26">26</xref>]. These positive effects may be mediated by a direct transdifferentiation of transplanted stem cells to cardiomyocytes [<xref ref-type="bibr" rid="B37">37</xref>], but also indirectly by parackrine secretion of cytokines and growth factors with resulting stimulation of survivors cardiac stem cells and/or angiogenesis, improving microvascular function [<xref ref-type="bibr" rid="B38">38</xref>]. Recently, a stabilizing effect of the injection cells via changes in the connettive tissue has been hypothesized [<xref ref-type="bibr" rid="B39">39</xref>].</p>
      <p>Stem cells are easily obtained from the bone marrow with a minimally invasive approach and can be easily transplanted into the osteonecrotic lesion as demonstrated in our patient. This simple, cheap procedure allowed a clinical improvement of symptoms, and induced novel ossification as demonstrated by CT scan 15 months after the treatment, and it must be emphasized that the patient is in complete remission from a stage 3 BRONJ after 30 months. In addition, our patient showed a particularly rich bone marrow, not only in red cells precursors (as we expected since the patient was treated with EPO), but also in total stem cells subset (table <xref ref-type="table" rid="T1">1</xref>). Recently, Kikuiri et al, [<xref ref-type="bibr" rid="B40">40</xref>] infused mesenchymal stem cells in BRONJ-like mice. They demonstrated that systemic infusion with MSCs prevents and cures BRONJ-like disease possibly via introduction of peripheral tolerance, shown as an inhibition of T-helper-producing interlukin 17 cells (th17)and increase in T regulatory cells (Tregs). Handschel and Meyer [<xref ref-type="bibr" rid="B41">41</xref>] suggest that stem cells might be a promising treatment option for BRONJ and our case demonstrates their hypothesis is right. In our case bone marrow stem cells were directly infused in the bone lesion of BRONJ with a complete remission.</p>
      <p>We are aware that a case report can be of limited interest, however it could suggest that this technique may be studied in patients with BRONJ unrensponsive to standard treatment and can be tried before major demolitive surgery procedures for the reconstruction of defect of the ONJ by bisphosphonates.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>All authors read and approved the final manuscript. LC, MA, LC conceived of the study, and participated in its design and coordination and helped to draft the manuscript. AO, MM have been involved in drafting the manuscript and to collect the results from follow-up examinations. MP has been involved in revising the manuscript critically for important intellectual content. DV, AZ, CDN have done substantial contributions to conceptions to conception and design and interpretation of data.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>Authors acknowledge Fondazione di Piacenza e Vigevano (Italy) for the excellent support and assistence</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McClug</surname>
            <given-names>MR</given-names>
          </name>
          <article-title>Bisphosphonates</article-title>
          <source>Endocrinol Metab Clin North Am</source>
          <year>2003</year>
          <volume>32</volume>
          <comment>253 71</comment>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Santini</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vespasiani Gentilucci</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Vincenzi</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Picardi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vasaturo</surname>
            <given-names>F</given-names>
          </name>
          <article-title>The antineoplastic role of bisphosphonates: from basic research to clinical evidence</article-title>
          <source>Ann Oncol</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>1468</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdg401</pub-id>
          <pub-id pub-id-type="pmid">14504045</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Boissier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Magnetto</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Frappart</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cuzin</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Ebetino</surname>
            <given-names>FH</given-names>
          </name>
          <name>
            <surname>Delmas</surname>
            <given-names>PD</given-names>
          </name>
          <article-title>Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices</article-title>
          <source>Cancer Res</source>
          <year>1997</year>
          <volume>57</volume>
          <fpage>3890</fpage>
          <lpage>3894</lpage>
          <pub-id pub-id-type="pmid">9307266</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wysoski</surname>
            <given-names>DK</given-names>
          </name>
          <article-title>Reports of esophageal cancer with oral bisphosphonates use</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>89</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc0808738</pub-id>
          <pub-id pub-id-type="pmid">19118315</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ibrahim</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Barbanti</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Giorgio Marrano</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Mercatali</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ronconi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vicini</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Osteonecrosis of the Jaw in patients with bone matastases treated with bisphosphonates: a retrospective study</article-title>
          <source>Oncologist</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>330</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="doi">10.1634/theoncologist.2007-0159</pub-id>
          <pub-id pub-id-type="pmid">18378544</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bagan</surname>
            <given-names>JV</given-names>
          </name>
          <name>
            <surname>Jimenez</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Murillo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hernandez</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Poveda</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Sanchis</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases</article-title>
          <source>Oral oncol</source>
          <year>2006</year>
          <volume>42</volume>
          <fpage>327</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="doi">10.1016/j.oraloncology.2005.08.001</pub-id>
          <pub-id pub-id-type="pmid">16275156</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hewitt</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Farah</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Bisphosphonates-related osteonecrosis of the jaws: a comprehensive review</article-title>
          <source>J Oral Pathol Med</source>
          <year>2007</year>
          <volume>36</volume>
          <fpage>319</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0714.2007.00540.x</pub-id>
          <pub-id pub-id-type="pmid">17559492</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <collab>American Dental Association Council on Scientific Affairs</collab>
          <article-title>Dental Management of patients receiving oral bisphosphonate Therapy: Expert panel recommendations</article-title>
          <source>J Am Assoc</source>
          <year>2006</year>
          <volume>137</volume>
          <fpage>1144</fpage>
          <lpage>1150</lpage>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cavanna</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bert&#xE8;</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Arcari</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mordenti</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pagani</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Vallisa</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Osteonecrosis of the Jaw. A newly emerging sete-specific osseous pathology in opatients with cancer treated with bisphosphonates. Report of 5 cases and review of the literature</article-title>
          <source>Eur J Internal Med</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>417</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejim.2006.10.008</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rizzoli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Burlet</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Cahall</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Delmas</surname>
            <given-names>PD</given-names>
          </name>
          <name>
            <surname>Eriksen</surname>
            <given-names>EF</given-names>
          </name>
          <name>
            <surname>Felsenberg</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis</article-title>
          <source>Bone</source>
          <year>2008</year>
          <volume>42</volume>
          <fpage>841</fpage>
          <lpage>847</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bone.2008.01.003</pub-id>
          <pub-id pub-id-type="pmid">18314405</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Marx</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Sawatari</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Fortin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Broumand</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2005</year>
          <volume>63</volume>
          <fpage>1567</fpage>
          <lpage>1575</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joms.2005.07.010</pub-id>
          <pub-id pub-id-type="pmid">16243172</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yarom</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Yahalom</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Shoshani</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hamed</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Regev</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Elad</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and teatment outcome</article-title>
          <source>Osteoporos Int</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>1363</fpage>
          <lpage>1370</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-007-0384-2</pub-id>
          <pub-id pub-id-type="pmid">17598065</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Elad</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yarom</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Hamed</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Ayalon</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yahalom</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Regev</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Osteomyelitis and necrosis of the jaw in patients treated with bisphosphonates A comparative study</article-title>
          <source>Clin Lab Haematol</source>
          <year>2006</year>
          <volume>28</volume>
          <fpage>393</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2257.2006.00841.x</pub-id>
          <pub-id pub-id-type="pmid">17105493</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ruggiero</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Fantasia</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Carlson</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Bisphosphonates-related osteonecrosis of the jaw: background and guidlines for diagnosis, staging and management</article-title>
          <source>Oral Surg. Oral Med Oral Path Oral Radio Endod</source>
          <year>2006</year>
          <volume>102</volume>
          <fpage>433</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tripleo.2006.06.004</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vescovi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Merigo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Meleti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fornaini</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bonanini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rocca</surname>
            <given-names>EP</given-names>
          </name>
          <name>
            <surname>De Moor</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Nammour</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Surgical treatment of maxillary osteonecrosis due to bisphosphonates using an Er: YAG (2940 nm) laser. Discussion of 17 clinical cases</article-title>
          <source>Rev Belge Med Dent</source>
          <year>2009</year>
          <volume>64</volume>
          <issue>2</issue>
          <fpage>87</fpage>
          <lpage>95</lpage>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rugani</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Stephan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Truschnegg</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Obermayer-Pietsch</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Jakse</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Bisphosphonate - associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report</article-title>
          <source>OOOOE</source>
          <year>2010</year>
          <volume>110</volume>
          <fpage>e1</fpage>
          <lpage>e6</lpage>
          <pub-id pub-id-type="pmid">21112522</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ruggiero</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Dodson</surname>
            <given-names>TB</given-names>
          </name>
          <name>
            <surname>Assale</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Landesberg</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Marx</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Mehrotra</surname>
            <given-names>B</given-names>
          </name>
          <article-title>American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Relate Osteonecrosis of the Jaws-2009 Update</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2009</year>
          <volume>67</volume>
          <issue>Suppl</issue>
          <fpage>2</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">19371809</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Madrid</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bouferrache</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Abarca</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jaques</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Broome</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Bisphosphonate-related osteonecrosis of the jaws: how to manage cancer patients</article-title>
          <source>Oral Oncology</source>
          <year>2010</year>
          <volume>46</volume>
          <fpage>468</fpage>
          <lpage>470</lpage>
          <pub-id pub-id-type="doi">10.1016/j.oraloncology.2010.03.016</pub-id>
          <pub-id pub-id-type="pmid">20452814</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="other">
          <name>
            <surname>Lee</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Jeng</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Ching</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>HP</given-names>
          </name>
          <name>
            <surname>Kok</surname>
            <given-names>SH</given-names>
          </name>
          <article-title>Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy</article-title>
          <source>Wiley InterScience</source>
          <year>2010</year>
          <ext-link ext-link-type="uri" xlink:href="http://www.interscience.wiley.com">http://www.interscience.wiley.com</ext-link>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="other">
          <name>
            <surname>Wilde</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Heufelder</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Winter</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hendricks</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Frerich</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Schramm</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hemprich</surname>
            <given-names>A</given-names>
          </name>
          <article-title>The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw</article-title>
          <source>OOOOE</source>
          <year>2010</year>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Korbling</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Estrov</surname>
            <given-names>Z</given-names>
          </name>
          <article-title>Adult stem cells for tissue repair--a new therapeutic concept?</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <fpage>570</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra022361</pub-id>
          <pub-id pub-id-type="pmid">12904523</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Schneuder</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Puellen</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kramann</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Raupach</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Bornemann</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Knuechel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Perez-Buoza</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Neuss</surname>
            <given-names>S</given-names>
          </name>
          <article-title>The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds</article-title>
          <source>Biomaterial</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>467</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.09.059</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ruggiero</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gralow</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Marx</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Hoff</surname>
            <given-names>AO</given-names>
          </name>
          <name>
            <surname>Schubert</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Huryn</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Toth</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Damato</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Valero</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer</article-title>
          <source>J Oncol Prac</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>7</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1200/JOP.2.1.7</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gussoni</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Soneoka</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Strickland</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Buzney</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Khan</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Flint</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Kunkel</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Mulligan</surname>
            <given-names>RC</given-names>
          </name>
          <article-title>Dystrophin expression in the mdx mouse restored by stem cell transplantation</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>401</volume>
          <fpage>309</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="pmid">16862078</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Petersen</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Bowen</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Patrene</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Mars</surname>
            <given-names>WM</given-names>
          </name>
          <name>
            <surname>Sullivan</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Murase</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Boggs</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Greenberger</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Goff</surname>
            <given-names>JP</given-names>
          </name>
          <article-title>Bone marrow as a potential source of hepatic oval cells</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>284</volume>
          <fpage>1168</fpage>
          <lpage>1170</lpage>
          <pub-id pub-id-type="doi">10.1126/science.284.5417.1168</pub-id>
          <pub-id pub-id-type="pmid">10325227</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="other">
          <name>
            <surname>Piepoli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Vallisa</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Arbasi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cavanna</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cerri</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Mori</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Passerini</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Tommasi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Rossi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Capuccci</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Bone marrow cell transplantation improves cardiac, autonomic, and functional indexes in acute anterior myocardial infarction patients (Cardiac Study)</article-title>
          <source>European Journal of Heart Failure</source>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Marx</surname>
            <given-names>RE</given-names>
          </name>
          <article-title>Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2003</year>
          <volume>61</volume>
          <fpage>1115</fpage>
          <lpage>1117</lpage>
          <pub-id pub-id-type="doi">10.1016/S0278-2391(03)00720-1</pub-id>
          <pub-id pub-id-type="pmid">12966493</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Goodger</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Pogrel</surname>
            <given-names>MA</given-names>
          </name>
          <article-title>Osteonecrosis of the jawsmassociated with cancer chemotherapy</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2003</year>
          <volume>61</volume>
          <fpage>1104</fpage>
          <lpage>1107</lpage>
          <pub-id pub-id-type="doi">10.1016/S0278-2391(03)00328-8</pub-id>
          <pub-id pub-id-type="pmid">12966490</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Edwards</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Gounder</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>McKoy</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Boyd</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Farrugia</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Migliorati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Marx</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ruggiaero</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dimopoulos</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Raisch</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Singhal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Carson</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Obadina</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Trifilio</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>West</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mehta</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bennett</surname>
            <given-names>CL</given-names>
          </name>
          <article-title>Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilance and reporting of this serious adverse event</article-title>
          <source>Lancet Oncol</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>1166</fpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(08)70305-X</pub-id>
          <pub-id pub-id-type="pmid">19038763</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Salamon</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Toldy</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Use of mesenchymal stem cells from adult bone marrow for injured tissue repair</article-title>
          <source>Orv Hetil</source>
          <year>2009</year>
          <volume>150</volume>
          <issue>27</issue>
          <fpage>1259</fpage>
          <lpage>1265</lpage>
          <pub-id pub-id-type="doi">10.1556/OH.2009.28666</pub-id>
          <pub-id pub-id-type="pmid">19531459</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Connolly</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Grese</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lipello</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dehne</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Development of an osteogenic bone marrow preparation</article-title>
          <source>J Bone Joint Surg</source>
          <year>1989</year>
          <volume>71A</volume>
          <fpage>684</fpage>
          <lpage>691</lpage>
        </mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Muschler</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Boehm</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Easley</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume</article-title>
          <source>J Bone Joint Surg</source>
          <year>1997</year>
          <volume>79A</volume>
          <fpage>1699</fpage>
          <lpage>1707</lpage>
        </mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Usami</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Mizuno</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Okada</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Narita</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Aoki</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kondo</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Mizuno</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mase</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nishiguchi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kagami</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Minoru</surname>
            <given-names>U</given-names>
          </name>
          <article-title>Composite implantation of mesenchymal stem cells with endothelial progenitor cells enhances tissue-engineered bone formation</article-title>
          <source>J Biomed Mater Res A</source>
          <year>2009</year>
          <volume>90</volume>
          <issue>3</issue>
          <fpage>730</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">18570318</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bittira</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Shum-Tim</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Al-Khaldi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chiu</surname>
            <given-names>RC</given-names>
          </name>
          <article-title>Mobilization and homing of bone marrow stromal cells in Myocardial infarction</article-title>
          <source>Eur J Cardiotoracic Surg</source>
          <year>2003</year>
          <volume>24</volume>
          <fpage>393</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="doi">10.1016/S1010-7940(03)00325-7</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Prockop</surname>
            <given-names>DJ</given-names>
          </name>
          <article-title>Marrow stromal cells as stem cells for nonhematopoietic tissues</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>276</volume>
          <fpage>71</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1126/science.276.5309.71</pub-id>
          <pub-id pub-id-type="pmid">9082988</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Asahara</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Takahashi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Masuda</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kalka</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Iwaguro</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Inai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Silver</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Isner</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells</article-title>
          <source>EMBO J</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>3964</fpage>
          <lpage>3972</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/18.14.3964</pub-id>
          <pub-id pub-id-type="pmid">10406801</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Orlic</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kajstura</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chimenti</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bodine</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Leri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Anversa</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Bone marrow cells regenerate infracted myocardium</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>410</volume>
          <fpage>701</fpage>
          <lpage>705</lpage>
          <pub-id pub-id-type="doi">10.1038/35070587</pub-id>
          <pub-id pub-id-type="pmid">11287958</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Smart</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Riley</surname>
            <given-names>PR</given-names>
          </name>
          <article-title>The stem cell movement</article-title>
          <source>Circ Res</source>
          <year>2008</year>
          <volume>102</volume>
          <comment>1155 1168</comment>
        </mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sun</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Weisel</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Zhuo</surname>
            <given-names>YF</given-names>
          </name>
          <name>
            <surname>Yau</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Rk</given-names>
          </name>
          <name>
            <surname>Fazel</surname>
            <given-names>SS</given-names>
          </name>
          <article-title>Improvement in cardiac function after bone marrow cell therapy is associated with an increase in myocardial inflammation</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <year>2009</year>
          <volume>296</volume>
          <fpage>H43</fpage>
          <lpage>H50</lpage>
          <pub-id pub-id-type="pmid">19011044</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kikuiri</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kin</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Yamaza</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Akiyama</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>le</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw - like disease in mice</article-title>
          <source>J Bone Miner Res</source>
          <year>2010</year>
          <volume>25</volume>
          <issue>7</issue>
          <fpage>1668</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="doi">10.1002/jbmr.37</pub-id>
          <pub-id pub-id-type="pmid">20200952</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Handschel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>U</given-names>
          </name>
          <article-title>Infection, vascularization, remodelling - are stem cell the answers for bone disease of the jaw?</article-title>
          <source>Head &amp; Face Medicine</source>
          <year>2011</year>
          <volume>7</volume>
          <fpage>5</fpage>
          <pub-id pub-id-type="doi">10.1186/1746-160X-7-5</pub-id>
          <pub-id pub-id-type="pmid">21332971</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
